CDE innate response for targets webinar

390 views

Published on

Published in: Business, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
390
On SlideShare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
5
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

CDE innate response for targets webinar

  1. 1. Centre Defence Enterprise for Themed Competition Webinar
  2. 2. © Crown copyright 2013 Dstl 20 May 2014
  3. 3. The aim of CDE Technology Best providers Barriers
  4. 4. 20 May 2014 Funding research
  5. 5. Two routes to funding Enduring Themed
  6. 6. Themed competition Requirements Bounded Specific
  7. 7. CDE themed competition Innate response targets for therapy
  8. 8. Enduring challenge competition Perpetual Radical £3M per year
  9. 9. Dstl is part of the Ministry of Defence UNCLASSIFIED / For Public Release Centre for Defence Enterprise www.science.mod.uk/enterprise cde@dstl.gov.uk Crown Copyright Dstl 2012 Enduring challenges • protection • situational awareness • power • communications • data • lethality • mobility • human performance • lower cost of ownership • new capabilities
  10. 10. Online bid submission CDE Portal Only route Low overhead
  11. 11. Dstl is part of the Ministry of Defence UNCLASSIFIED / For Public Release Centre for Defence Enterprise www.science.mod.uk/enterprise cde@dstl.gov.uk Crown Copyright Dstl 2012 Read available information Start with – Quick Start Guide CDE Portal
  12. 12. Intellectual property
  13. 13. Dstl is part of the Ministry of Defence UNCLASSIFIED / For Public Release Centre for Defence Enterprise www.science.mod.uk/enterprise cde@dstl.gov.uk Crown Copyright Dstl 2012 Register now
  14. 14. CDE Innovation Network
  15. 15. Innate response targets for therapy CDE themed competition March 25 - June 5 2014 20 May 2014
  16. 16. Key dates • Competition launches today • Presentation to follow • Opportunity for Q&A • Webinar Tuesday 1 April • Deadline for applications Thursday 5 June 2014 at 17:00 hrs via Centre for Defence Enterprise Portal • Funding decisions to be made July 2014 • Notifications end July © Crown copyright 2014 Dstl 20 May 2014
  17. 17. Background: biothreat agents • Pathogenic for man or animals • Very low infectious dose • Infectious via the inhalational route • Cause endemic disease around world • Usually are zoonotic diseases • Lethal or incapacitating © Crown copyright 2014 Dstl 20 May 2014
  18. 18. © Crown copyright 2014 Dstl 20 May 2014 Defence against biothreats • Many potential biothreat agents • How to defend against them? • Impossible to make a vaccine/therapy for every potential agent • Require generic therapy
  19. 19. Generic approach to therapy • By influencing the host response • Requires an understanding of the host response to pathogen & safe ways to influence it • Requires identification of relevant targets or pathways in the host 20 May 2014 © Crown copyright 2014 Dstl
  20. 20. Innate (host) response targets for therapy • Objective of this competition is to look broadly across research and development to identify host cell targets and pathways • Using data derived from diverse infection models • Respondents to competition do not need to work directly with biothreat agents • Ultimate aim is to apply the most innovative approaches to biothreat agents 20 May 2014 © Crown copyright 2014 Dstl
  21. 21. CDE themed competition specifics • Seeking innovative proposals for short projects (<1year); £30- 80k guide; (£500k total budget) • Show proof-of-concept for your proposal; there is funding allocated for follow-on work for successful projects • Competition divided into 3 challenges • Respondents need to address 1 of the challenges, may address >1, do not have to address all 3 • Challenges described fully in the competition document • Bids must be ethical and compliant with UK government legislation 20 May 2014 © Crown copyright 2014 Dstl
  22. 22. Challenge 1 © Crown copyright 2014 Dstl 20 May 2014 Identification of new cellular or host pathway targets
  23. 23. Identification of new cellular or host pathway targets • In host-pathogen model of your choice – Does not need to be a biodefence pathogen – Does not need to be in vivo • Conditioning of cells ex vivo eg to profile responses or prior to adoptive transfer • Targeting cells in situ eg – to refocus them – to activate them – to induce them to traffic – to redirect them © Crown copyright 2014 Dstl 20 May 2014
  24. 24. Identification of new cellular or host pathway targets May involve the identification of eg • immuno stimulants • modulators • transfection factors • chemokines, cytokines or the induction (or blockade) of these • cytokine/chemokine/growth factor receptors and application of these to modulate host responses © Crown copyright 2014 Dstl 20 May 2014
  25. 25. Identification of new cellular or host pathway targets • Some of these may be exogenous and some endogenous factors • Some endogenous natural regulators /regulatory pathways may be exploited • to reduce inflammation and to restore homeostasis © Crown copyright 2014 Dstl 20 May 2014 Normal OveractiveUnderactive
  26. 26. Possible outcomes Proposals for – identification of new cellular targets /pathways – new applications of manipulating known cellular targets/pathways – demonstration that targets may be influenced beneficially, for example to: • prevent cytotoxicity • prevent/reduce microbial invasion • reduce microbial load • restore normal cell function © Crown copyright 2014 Dstl 20 May 2014
  27. 27. Challenge 2 Identification of new candidate therapies © Crown copyright 2014 Dstl 20 May 2014
  28. 28. Identification of new candidate therapies Exploit appropriate cellular targets and pathways to identify new therapies by, for example: • enhancing cell-mediated immunity • investigating novel combinations • identification and manipulation of significant transcription factors • micro RNA-directed therapies or antagonists © Crown copyright 2014 Dstl 20 May 2014
  29. 29. Possible outcomes • Candidate therapies should be druggable and generic • Proposals should show proof-of-concept • Does not exclude the re-purposing or augmentation of existing therapies © Crown copyright 2014 Dstl 20 May 2014
  30. 30. Challenge 3 Identification of new platform technologies © Crown copyright 2014 Dstl 20 May 2014
  31. 31. Identification of new platform technologies For assessing therapeutic benefit • Novel technologies such as: • non-invasive methods of in-vivo/ex-vivo analysis eg bio-imaging or tracking • Transcriptomics including micro RNA analysis • In-silico modelling of host responses • Novel assays to monitor the host immune response © Crown copyright 2014 Dstl 20 May 2014
  32. 32. Possible outcomes • New technologies which may facilitate the identification and development of candidate therapies • Proposals should demonstrate the impact of the technology on therapeutic development © Crown copyright 2014 Dstl 20 May 2014
  33. 33. What we want • Highly innovative approaches that are significantly different from existing technologies • Generally technology readiness level (TRL) ≤ 3 • Generic approaches (not pathogen specific) • Approaches applicable to intracellular pathogens where appropriate • Approaches that will lead to a feasible clinical product © Crown copyright 2014 Dstl 20 May 2014
  34. 34. What we don’t want Proposals that concern: • high technology readiness level (TRL) capability • serological targets only (rather than cellular) • antibody-based therapies (but antibodies as a targeting mechanism are acceptable) • existing solutions or technology already tested and found to have limited utility • a paper study or review or similar • pre-exposure therapies or therapeutics • topical therapies for wounds © Crown copyright 2014 Dstl 20 May 2014
  35. 35. Successful proposals • Each will be assigned a Technical Partner – Provides interface between project and defence community – If project successful, potential routes to exploitation developed © Crown copyright 2014 Dstl 20 May 2014
  36. 36. Summary • Competition launches today • Webinar Tuesday 1 April • Closes on Thursday 5 June 2014 at 17:00 hrs • Short proof-of-concept proposals • If successful, potential for follow-on funding • May include additional research to develop technology for MOD • Competition information available on CDE website www.science.mod.uk © Crown copyright 2014 Dstl 20 May 2014
  37. 37. Questions? © Crown copyright 2014 Dstl 20 May 2014
  38. 38. Dstl is part of the Ministry of Defence UNCLASSIFIED / For Public Release Centre for Defence Enterprise www.science.mod.uk/enterprise cde@dstl.gov.uk Crown Copyright Dstl 2012 e: cde@dstl.gov.uk w: www.science.mod.uk @dstlmod #dstlcde LinkedIn group – search ‘Centre for Defence Enterprise’ Keep in touch

×